Experimental Alzheimer’s drug shows promise in trial
LINCOLN, Neb. (KLKN) – There’s some encouraging news about an experimental drug used to slow the progression of Alzheimer’s disease.
The drug is called Lecanemab.
The research shows Lecanemab reduced symptoms of the disease by 27%.
Patients with early signs of Alzheimer’s showed less cognitive and functional decline after taking the drug compared with a placebo group.
The drug’s makers say they will apply for FDA approval by March.
The agency says it will prioritize its review of the drug.
Researchers say while Lecanemab shows promise, the drug also had some side effects such as headaches, brain swelling and brain bleeding.